Skip to main content
OpenTrials
Completed

NCT Number: NCT00482235

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • You are between the ages of 40 and 75
  • You have had a history for at least a year of COPD symptoms
  • You have a history of smoking one pack of cigarettes per day for 10 years

Exclusion criteria

  • You have been in a research study with an investigational drug or vaccine in the last 4 weeks.
  • You have donated blood in the last 4 weeks.
  • You have been hospitalized or had major surgery in the last 4 weeks
  • You have been treated in the emergency room within the last 2 months or hospitalized within the last 3 months for your COPD symptoms
  • You have a history of heart problems in the last 6 months
  • You have a history of stomach problems
  • You are unwilling to avoid grapefruit juice throughout the study

Treatment and study plan

MK0359

Drug

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Important dates

Study start
2002
Primary completion
2003
Study completion
2003
First posted
Jun 5, 2007
Registry last updated
Dec 2, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.